Abstract
In 2021, 273 Rocky Mountain Spotted Fever cases have been reported nationwide. In Chihuahua City, fourteen samples were obtained from children suspected of rickettsial infection. The analysis of samples collected from January to December 2021 showed a prevalence of 28.5%, 43% and 28.5% for Rickettsia rickettsii, Ehrlichia canis, and both pathogens in coinfection, respectively. The analysis of clinical hematological and biochemistry analytes showed alterations such as 100% of the children coursed with elevated liver enzymes and coagulation times, 64% showed leukocytosis due to neutrophilia, 55% of them had thrombocytopenia, lymphopenia and hypoalbuminemia, and 45% showed normocytic normochromic anemia. Statistically significant differences were obtained in the chemokines IL-8, RANTES, CXCL9/MIG, and CXCL10/IP-10 across the coinfected and control groups; the differences in IP-10 were significant for patients infected by R. rickettsii compared to the control group. Also, significant differences were observed for IL-1β, IL-6, IL-17, IFNγ, and TNFα among the R. rickettsii positive group compared to the control group; on the other hand; the coinfected group exhibited modified levels of IL-6, IL-8, and IL-10 compared with the control group. Finally, significant differences were obtained for CD8 + T lymphocytes subpopulations between positive individuals for R. rickettsii and E. canis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
GPES sincerely acknowledges funding from Consejo Nacional de Ciencia y Tecnologi?a (CONACYT), Ciencia Básica Grant No. A1-S-53789. GPES as part of Laboratorio Nacional de Citometría de Flujo appreciates the support from CONACYT- Apoyos para Acciones de Fortalecimiento, Articulación de Infraestructura y Desarrollo de Proyectos Científicos, Tecnológicos y de Innovación en Laboratorios Nacionales Grant No. 315807. LPR, BEEA, CAG is, 1071642, 790272, 764775 supported from CONACYT, Programa de Becas Nacionales from UACH (Scholarship numbers, respectively).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol complied with the guidelines established in the Regulations of the General Health Law in matters of health research, the Declaration of Helsinki, and the Good Clinical Practices issued by the National Bioethics Commission. The Research Ethics Committee also approved it of the Faculty of Medicine and Biomedical Sciences of the Autonomous University of Chihuahua with registration number CI-056-19. A written statement that formal consent was obtained from the parent/guardian.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
